Key facts
- Prokarium’s last known valuation is $109.4M (Feb 2023).
- It has raised $88.8M; the latest was Later Stage VC ($6.3M) in Dec 2025.
- Notable investors include Innovate UK, Korea Investment Partners, London & Partners., British Business Bank, Wellcome Trust — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Prokarium
- ·The full record, as it builds
Funding rounds
No funding rounds for Prokarium are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Prokarium
Operator of a biopharmaceutical company intended for developing bacterial immunotherapies for cancer. The company's proprietary technology naturally homes to tumors, stimulates anti-tumor immune responses, and can be programmed to deliver therapeutic agents directly inside the tumor microenvironment, targeting non-muscle invasive bladder cancer, enabling the healthcare industry to treat patients with cancers whose tumors resist or do not respond well to current immunotherapies.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2012
- Employees
- 18
- Website
- prokarium.com/
- Ownership
- Privately Held (backing)
Prokarium doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prokarium shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prokarium in its N-PORT filings yet. We sweep new filings monthly.